FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome.

Patients that had received adjuvant endocrine therapy showed a trend toward a greater decrease (Δ%) of FOXA1 expression levels in pleural metastases compared to the primary tumor vs. patients that had not received adjuvant therapy ( P = 0.085; Mann–Whitney U‐test; Fig. 2 B), while this was not the case for GATA3 ( P = 0.779; Mann–Whitney U‐test).

also in 53,322 other papers